| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3a56475044b1f462f10abba64f0d39f6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_84b17242e15ef654702379d1e079d8fa |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-567
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-465
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-303
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B15-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B15-30 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16B15-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16B15-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G06G7-58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-00 |
| filingDate |
2007-03-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0ba1276037d0a5a73eb588e01a9c4019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d100b3560cfcad4202dad7f0489dd09f |
| publicationDate |
2009-05-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2009130102-A1 |
| titleOfInvention |
Methods for humanizing antibodies and humanized antibodies made thereby |
| abstract |
Disclosed herein is the use of three-dimensional structure information to guide the process of modifying antibodies with amino acids from one or more templates or surrogates such that the antigen binding properties of the parent antibody are maintained and the immunogenicity potential is reduced when administered as a therapeutic in humans. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10940212-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108475299-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017093435-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10787510-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2019111148-A1 |
| priorityDate |
2006-03-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |